Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.

Phosphorylation is involved in numerous neurodegenerative diseases. In particular, alpha-synuclein is extensively phosphorylated in aggregates in patients suffering from synucleinopathies. However, the share of this modification in the events that lead to the conversion of alpha-synuclein to aggregated toxic species needed to be clarified. The rat model that we developed through rAAV2/6-mediated expression of alpha-synuclein demonstrates a correlation between neurodegeneration and formation of small filamentous alpha-synuclein aggregates. A mutation preventing phosphorylation (S129A) significantly increases alpha-synuclein toxicity and leads to enhanced formation of beta-sheet-rich, proteinase K-resistant aggregates, increased affinity for intracellular membranes, a disarrayed network of neurofilaments and enhanced alpha-synuclein nuclear localization. The expression of a mutation mimicking phosphorylation (S129D) does not lead to dopaminergic cell loss. Nevertheless, fewer but larger aggregates are formed, and signals of apoptosis are also activated in rats expressing the phosphorylation-mimicking form of alpha-synuclein. These observations strongly suggest that phosphorylation does not play an active role in the accumulation of cytotoxic pre-inclusion aggregates. Unexpectedly, the study also demonstrates that constitutive expression of phosphorylation-mimicking forms of alpha-synuclein does not protect from neurodegeneration. The role of phosphorylation at Serine 129 in the early phase of Parkinson's disease is examined, which brings new perspective to therapeutic approaches focusing on the modulation of kinases/phosphatases activity to control alpha-synuclein toxicity.

[1]  S. Scarlata,et al.  Membrane binding and self-association of alpha-synucleins. , 2001, Biochemistry.

[2]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[3]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[4]  David W. Miller,et al.  Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.

[5]  E. Masliah,et al.  Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases , 2007, NeuroMolecular Medicine.

[6]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[7]  E. Eves,et al.  Activation of Raf-1 Signaling by Protein Kinase C through a Mechanism Involving Raf Kinase Inhibitory Protein* , 2003, The Journal of Biological Chemistry.

[8]  J. Trojanowski,et al.  Concurrence of α-synuclein and tau brain pathology in the Contursi kindred , 2002, Acta Neuropathologica.

[9]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[10]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. , 2007, Journal of neuroscience research.

[11]  Erika K Wallender,et al.  Optical Reporters for the Conformation of α-Synuclein Reveal a Specific Interaction with Mitochondria , 2008, The Journal of Neuroscience.

[12]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[13]  J. Trojanowski,et al.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. , 2002, The Journal of biological chemistry.

[14]  David W. Miller,et al.  α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication , 2004, Neurology.

[15]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[16]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[17]  D. Price,et al.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[18]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[19]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[20]  L. Meijer,et al.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.

[21]  A. Kakita,et al.  Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. , 2008, Archives of neurology.

[22]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[23]  P. Lansbury,et al.  Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.

[24]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[25]  Sang-Hyeon Lee,et al.  Casein Kinase II-mediated Phosphorylation Regulates α-Synuclein/Synphilin-1 Interaction and Inclusion Body Formation* , 2004, Journal of Biological Chemistry.

[26]  R. Brandt,et al.  Conversion of Serine to Aspartate Imitates Phosphorylation-induced Changes in the Structure and Function of Microtubule-associated Protein Tau* , 1997, The Journal of Biological Chemistry.

[27]  A. Schapira,et al.  Causes of neuronal death in Parkinson's disease. , 2001, Advances in neurology.

[28]  He-Jin Lee,et al.  Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  N. Hattori,et al.  Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. , 1995, Biochimica et biophysica acta.

[30]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[31]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[32]  E. Leithe,et al.  Connexin43 synthesis, phosphorylation, and degradation in regulation of transient inhibition of gap junction intercellular communication by the phorbol ester TPA in rat liver epithelial cells. , 2005, Experimental cell research.

[33]  M. Beal.  Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment , 2004, Journal of bioenergetics and biomembranes.

[34]  W. Poewe,et al.  Glial cell death induced by overexpression of alpha-synuclein. , 2001, Journal of neuroscience research.

[35]  J. Trojanowski,et al.  Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. , 2002, Acta neuropathologica.

[36]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[38]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[39]  W. Poewe,et al.  Glial cell death induced by overexpression of α‐synuclein , 2001 .

[40]  R. Brennan,et al.  Analysis of the Structural Properties of cAMP-responsive Element-binding Protein (CREB) and Phosphorylated CREB* , 1996, The Journal of Biological Chemistry.

[41]  T. Iwatsubo,et al.  Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. , 2006, The Journal of biological chemistry.

[42]  N. Gonatas,et al.  The involvement of the Golgi apparatus in the pathogenesis of amyotrophic lateral sclerosis, Alzheimer’s disease, and ricin intoxication , 1998, Histochemistry and Cell Biology.

[43]  T. Iwatsubo,et al.  Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease , 2004, Journal of neurochemistry.

[44]  S. Mukherjee,et al.  A caspase cleavage fragment of p115 induces fragmentation of the Golgi apparatus and apoptosis , 2002, The Journal of cell biology.

[45]  D. Kirik,et al.  Viral Vector Mediated Overexpression of Human α-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease , 2005, CNS Spectrums.

[46]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[47]  Seung-Jae Lee,et al.  Impairment of microtubule‐dependent trafficking by overexpression of α‐synuclein , 2006 .

[48]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[49]  R. Ridley,et al.  Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.

[50]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[51]  E. Masliah,et al.  alpha-synuclein promotes mitochondrial deficit and oxidative stress. , 2000, The American journal of pathology.

[52]  Mark P Mattson,et al.  Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. , 2006, Antioxidants & redox signaling.

[53]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[54]  R. Swerdlow,et al.  Complex I deficiency in Parkinson's disease frontal cortex , 2008, Brain Research.

[55]  V. Bader,et al.  Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. , 2007, Human molecular genetics.

[56]  R. Marienfeld,et al.  Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-κB control , 2001, Oncogene.

[57]  T. Iwatsubo,et al.  Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation* , 2006, Journal of Biological Chemistry.

[58]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[59]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[60]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[61]  R. Marconi,et al.  ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease , 2007, Neurology.

[62]  M. Parihar,et al.  Mitochondrial association of alpha-synuclein causes oxidative stress , 2008, Cellular and Molecular Life Sciences.

[63]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[64]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[65]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[66]  M. Feany,et al.  Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.

[67]  V. Uversky,et al.  Nuclear localization of alpha-synuclein and its interaction with histones. , 2003, Biochemistry.

[68]  C. Ross,et al.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  T. Iwatsubo,et al.  Accumulation of phosphorylated α‐synuclein in dopaminergic neurons of transgenic mice that express human α‐synuclein , 2007 .

[70]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[71]  J. Trojanowski,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[72]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[73]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[74]  D. Price,et al.  Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death , 2006, The Journal of Neuroscience.

[75]  M. Kay,et al.  Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  Peter T Lansbury,et al.  Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. , 2003, Biochemistry.

[77]  H. Brown-Borg,et al.  Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells , 2008, Neuroscience Letters.

[78]  A. Cuervo,et al.  Chaperone-mediated autophagy in aging and neurodegeneration: Lessons from α-synuclein , 2007, Experimental Gerontology.

[79]  H. Levine.  Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[80]  A. Cuervo,et al.  Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein. , 2007, Experimental gerontology.

[81]  Yoichi Nakazato,et al.  Pathology of the inferior olivary nucleus in patients with multiple system atrophy , 2002, Acta Neuropathologica.

[82]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[83]  R. Mandel,et al.  The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease , 2008, Proceedings of the National Academy of Sciences.

[84]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[85]  Fabrizio Chiti,et al.  Prefibrillar Amyloid Protein Aggregates Share Common Features of Cytotoxicity* , 2004, Journal of Biological Chemistry.

[86]  H. Wootz,et al.  ER stress and neurodegenerative diseases , 2006, Cell Death and Differentiation.

[87]  W. Scheper,et al.  Activation of the unfolded protein response in Parkinson's disease. , 2007, Biochemical and biophysical research communications.

[88]  C. Ross,et al.  Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. , 2005, Human molecular genetics.

[89]  E. Hirsch,et al.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[90]  T. Iwatsubo,et al.  The Role of G-Protein-Coupled Receptor Kinase 5 in Pathogenesis of Sporadic Parkinson's Disease , 2006, The Journal of Neuroscience.

[91]  R. Kayed,et al.  Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.

[92]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Hitoshi Takahashi,et al.  α-Synuclein pathology in the neostriatum in Parkinson’s disease , 2008, Acta Neuropathologica.

[94]  B. A. Hamilton.  alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates. , 2004, Genomics.

[95]  Colin L Masters,et al.  Linker histone H1 binds to disease associated amyloid-like fibrils. , 2006, Journal of molecular biology.

[96]  T. Maniatis,et al.  Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. , 1995, Genes & development.

[97]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[98]  R. Takahashi,et al.  Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. , 2007, Antioxidants & redox signaling.

[99]  J. Benovic,et al.  Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.

[100]  A. Singleton,et al.  Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .

[101]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[102]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[103]  Tianhong Pan,et al.  The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. , 2008, Brain : a journal of neurology.

[104]  Hideo Fujiwara,et al.  Accumulation of phosphorylated alpha-synuclein in aging human brain. , 2003, Journal of neuropathology and experimental neurology.

[105]  J. Bradbury.  Alpha-synuclein gene triplication discovered in Parkinson's disease. , 2003, The Lancet. Neurology.

[106]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.

[107]  V. Uversky,et al.  Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .

[108]  Seung-Jae Lee,et al.  Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. , 2006, The European journal of neuroscience.

[109]  A. Kakita,et al.  alpha-Synuclein pathology in the neostriatum in Parkinson's disease. , 2008, Acta neuropathologica.

[110]  W. Tatton,et al.  Apoptosis in Parkinson's disease: Signals for neuronal degradation , 2003, Annals of neurology.

[111]  L. Petrucelli,et al.  Gene dosage and pathogenesis of Parkinson's disease. , 2005, Trends in molecular medicine.

[112]  V. Allan,et al.  Caspase-mediated cleavage of the stacking protein GRASP65 is required for Golgi fragmentation during apoptosis , 2002, The Journal of cell biology.

[113]  N. Tatton.  Increased Caspase 3 and Bax Immunoreactivity Accompany Nuclear GAPDH Translocation and Neuronal Apoptosis in Parkinson's Disease , 2000, Experimental Neurology.

[114]  T. Iwatsubo,et al.  Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies , 2008, Experimental Neurology.

[115]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[116]  T. Iwatsubo,et al.  Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy , 2004, Acta Neuropathologica.

[117]  Christian Haass,et al.  Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain , 2000, The Journal of Neuroscience.

[118]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[119]  N. Gonatas,et al.  Fragmentation of the Golgi apparatus of the ballooned neurons in patients with corticobasal degeneration and Creutzfeldt-Jakob disease , 2000, Acta Neuropathologica.

[120]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[121]  S. Hersch,et al.  A Novel Procedure for Pre-embedding Double Immunogold–Silver Labeling at the Ultrastructural Level , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[122]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[123]  D. Housman,et al.  New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions , 2006, Cell cycle.

[124]  A. Singleton,et al.  Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.

[125]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[126]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[127]  Yukio Fujita,et al.  Fragmentation of Golgi apparatus of nigral neurons with α-synuclein-positive inclusions in patients with Parkinson’s disease , 2006, Acta Neuropathologica.